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Abstract
To understand the underlying signaling events of polyunsaturated fatty acid-induced growth, we studied the effect of
cAMP on early and delayed growth response events induced by linoleic acid in smooth muscle cells (SMC). cAMP
significantly inhibited both basal and linoleic acid-induced DNA synthesis. Linoleic acid-induced early growth response
events, such as activation of ERKs, induction of expression of c-fos and jun-B and stimulation of AP-1 activity, however,
were not affected by cAMP. In contrast, linoleic acid-induced c-jun expression was blocked by cAMP. cAMP alone
stimulated ERKs activation, c-fos and jun-B expression and increased AP-1 activity. Linoleic acid induced depletion of
p27kip1 and increased CDK2 activity, events required for G1/S transition. In contrast to early growth response events, linoleic
acid-induced G1/S transition signals were significantly inhibited by cAMP. These findings suggest that in addition to
inducing immediate early growth response events, linoleic acid mimics growth factors in activating cell cycle events that are
associated with G1/S transition in SMC and the negative regulation of linoleic acid-induced growth by cAMP is apparently
due to its antagonism with linoleic acid-induced p27kip1 depletion and CDK2 activation. ß 1998 Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Linoleic acid, a cis-polyunsaturated fatty acid,
modulates growth in several cell types [1,2]. Speci¢-
cally, it stimulates the growth of hepatoma cells and
enhances the proliferative responsiveness of mam-
mary epithelial cells and ¢broblasts to insulin and
epidermal growth factor (EGF), respectively [1^3].
Furthermore, transgenic mice over-expressing group
II phospholipase A2, a rate-limiting enzyme for the
generation of polyunsaturated fatty acids [4], develop
skin epidermal hyperplasia [5]. Recently we reported
that linoleic acid induces growth in arterial smooth
muscle cells (SMC) [6].
Activation of extracellular signal-regulated kinases
(ERKs) is an integral part of mitogen-induced early
growth response events in mammalian cells [7,8].
ERKs, which are distal in the ‘Ras-Raf-MEK-
ERK’ signaling kinase cascade (also known as
0167-4889 / 98 / $ ^ see front matter ß 1998 Published by Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 8 ) 0 0 0 9 8 - 6
* Corresponding author. 9.138 Medical Research Building,
University of Texas Medical Branch, 301 University Boulevard,
Rt. 1064, Galveston, TX 77555-1064, USA.
Fax: +1 (409) 747-0692; E-mail : grao@utmb.edu
BBAMCR 14370 13-10-98
Biochimica et Biophysica Acta 1405 (1998) 139^146
‘ERK MAPK’ pathway), are activated by dual phos-
phorylation on threonine and tyrosine residues cata-
lyzed by their immediate upstream kinases, MEK1/2
[9]. MEKs, in turn, are activated by a serine/threo-
nine kinase, Raf-1 [10^13]. Raf appears to be at the
converging end of signals from various upstream
events including Ras and protein kinase C (PKC)
[14,15]. Once activated, ERKs translocate to the nu-
cleus and modulate gene transcription via phosphor-
ylation and activation of transcriptional factors, such
as ternary complex factor Elk1 [7,8,16,17]. In addi-
tion, several studies have demonstrated a cross-talk
between the ‘ERK MAPK’ pathway and protein kin-
ase A [18^20]. These studies showed that agents
which increase intracellular cAMP antagonize
growth factor-induced mitogenesis by interfering
with the ‘ERK MAPK’ pathway at the Raf-1 level
in some cell types [19,20].
Cyclin-dependent kinases (CDKs) play an impor-
tant role in the regulation of cell growth [21^25]
and were thought to transduce mitogen-induced
early response signals to delayed events, such as
the DNA synthesis [21^25]. The activities of these
enzymes are regulated by positive and negative
modulators of the cell cycle known as cyclins and
CDK inhibitors (CDKIs) [24^30]. In fact, CDKs
require association with cyclins for their activity
[31^33]. For instance, CDK4 requires complex for-
mation with cyclin D for its activity, as does CDK2
with cyclin E [32,33]. Sequential activation of cyclin
D1-CDK4, cyclin E-CDK2, cyclin A-CDK2, and
cyclin B1-Cdc2 (CDK1) has been reported to be
required for the orderly progression through G1,
G1/S transition, S, G2/M transition of the cell cycle,
respectively [31^33]. The negative regulation of cy-
clin-CDKs depends on endogenous levels of CDKIs,
such as p27kip1 [26^30]. Indeed, recent reports
showed that transforming growth factor-L (TGF-L)
and cAMP-induced growth arrest in Mv1Lu mink
epithelial cells and macrophages is due to induced
expression of p27kip1 and its interference with cyclin
E-CDK2 and cyclin D1-CDK4 activities [34^36]. In
addition, higher steady-state levels of p27kip1 have
been reported in growth-arrested cells and its deple-
tion caused cells to enter into the S phase [35^37].
These ¢ndings indicate that p27kip1 is an essential
component in connecting early growth response
events to delayed e¡ects such as DNA synthesis
[38]. The purpose of the present study is to elucidate
the mitogenic signaling events induced by linoleic
acid and to investigate whether cAMP inhibits lino-
leic acid-induced growth in SMC. Here, we report
that in addition to inducing immediate early growth
response events, linoleic acid mimics growth factors
in activating cell cycle events associated with G1/S
transition. cAMP abrogates linoleic acid-induced
growth by apparently antagonizing linoleic acid-
induced p27kip1 depletion and CDK2 activa-
tion.
2. Materials and methods
2.1. Materials
Aprotinin, ATP, dibutyryl cyclic AMP (dcAMP),
histone H1, linoleic acid, leupeptin, myelin basic pro-
tein (MBP), phenylmethylsulfonyl £uoride (PMSF),
and sodium orthovanadate (Na3VO4) were obtained
from Sigma (St. Louis, MO). Anti-ERK1, anti-
ERK2, anti-CDK2, anti-c-fos, anti-jun-B, anti-jun-
D, and anti-p27kip1 rabbit polyclonal antibodies
were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-c-jun rabbit polyclonal anti-
bodies were from Oncogene Science (Uniondale,
NY). AP-1 consensus double-stranded oligonucleo-
tide and T4 polynucleotide kinase were from Prom-
ega (Madison, WI). cAMP enzyme immunoassay
kit was purchased from Amersham (Arlington
Heights, IL). Cell proliferation kit 1 (3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT)) was from Boehringer Mannheim (Indiana-
polis, IN). [Q-32P]ATP (3000 Ci/mmol) and
[3H]thymidine (70 Ci/mmol) were obtained from
NEN-Dupont (Boston, MA).
2.2. Cell culture
SMC were isolated from the thoracic aortae of
200^250 g male Sprague^Dawley rats by enzymatic
digestion as described earlier [6]. Cells were grown in
Dulbecco’s modi¢ed Eagles medium (DMEM) sup-
plemented with 10% (v/v) heat-inactivated calf se-
rum, 100 U/ml penicillin and 100 Wg/ml streptomy-
cin. Cultures were maintained at 37‡C in a
humidi¢ed 5% CO2 atmosphere.
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2.3. DNA synthesis
SMC were plated onto 60-mm dishes, allowed to
grow to 70^80% con£uence and then growth-arrested
by incubation in DMEM containing 0.1% calf serum
for 72 h. Growth-arrested SMC were exposed to li-
noleic acid (50 WM) in the presence and absence of
cAMP (1 mM) for 24 h. Cells were pulse-labeled with
1 WCi/ml [3H]thymidine for 2 h just before the end of
the incubation period and harvested by trypsiniza-
tion followed by centrifugation. The cell pellet was
resuspended in cold 10% trichloroacetic acid (TCA)
and vortexed vigorously to lyse the cells. The mixture
was allowed to sit on ice for 20 min and then passed
through a GF/F glass micro¢ber ¢lter. The ¢lter was
washed once with cold 5% TCA, and once with cold
70% ethanol, dried and placed in a liquid scintillation
vial containing the cocktail and the radioactivity was
measured in a liquid scintillation counter (Beckman
LS 3801).
2.4. Cell number
SMC were plated in a 96-well microtiter plate and
grew to 40% con£uence. Cells were then growth-ar-
rested by incubation in DMEM containing 0.1% calf
serum for 72 h. Growth-arrested SMC were treated
with and without linoleic acid (50 WM) in the pres-
ence and absence of cAMP (1 mM) for 4 days and
cell counts were determined by MTT assay according
to supplier’s instructions.
2.5. Western blot analysis
Growth-arrested SMC were treated with and with-
out linoleic acid (50 WM) in the presence and absence
of cAMP (1 mM) for the indicated time periods at
37‡C. Medium was aspirated, cells were rinsed with
cold phosphate-bu¡ered saline (PBS) and frozen im-
mediately in liquid nitrogen. Two hundred and ¢fty
microliters of lysis bu¡er (PBS, 1% NP-40, 0.5% so-
dium deoxycholate, 0.1% SDS, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 100 Wg/ml PMSF and 1 mM
Na3VO4) was added to the frozen monolayers,
thawed on ice for 15 min and scrapped into 1.5 ml
Eppendorf tubes. The cell lysates were cleared by
centrifugation at 12 000 rpm for 30 min at 4‡C. Pro-
tein content of the supernatants was determined us-
ing Bio-Rad’s Bradford reagent. Cell lysates contain-
ing equal amount of protein (40 Wg/lane) were
resolved by electrophoresis on a 0.1% SDS, 12%
polyacrylamide gel under reducing conditions. The
proteins were transferred electrophoretically to a ni-
trocellulose membrane (Hybond, Amersham). After
blocking in 10 mM Tris-Cl bu¡er (pH 8.0) contain-
ing 150 mM sodium chloride, 0.1% Tween 20 and 5%
(w/v) non-fat dry milk, the membrane was treated
with appropriate primary antibodies followed by in-
cubation with appropriate peroxidase-conjugated
secondary antibodies. The antigen^antibody com-
plexes were detected using chemiluminescence re-
agent kit (Amersham).
2.6. In-gel kinase assay
Cell lysates containing equal amounts of protein
(200 Wg) from control and each treatment were im-
munoprecipitated by incubating with anti-ERK2
antibodies for 2 h followed by addition of 40 Wl of
50% (w/v) protein A-Sepharose beads for an addi-
tional hour. The immunoprecipitates were resolved
on a 0.1% SDS, 10% polyacrylamide minigel that
was copolymerized with 350 Wg/ml MBP [39]. The
gel was washed twice for 30 min with 150 ml of
50 mM Tris-Cl bu¡er (pH 8.0) containing 20% iso-
propanol, and twice for 30 min with 150 ml of 50 mM
Tris-Cl bu¡er (pH 8.0) containing 5 mM L-mercap-
toethanol (bu¡er A). After incubation for 1 h in
150 ml of 6 M guanidine hydrochloride in bu¡er A
at room temperature, the gel was renatured by re-
peated washings with bu¡er A containing 0.04%
Tween 20 at 4‡C. The kinase reaction was performed
by incubating the gel in 30 ml of 40 mM HEPES
bu¡er (pH 8.0) containing 10 mM MgCl2, 0.5 mM
EGTA, 2 mM DTT, 50 WM ATP and 5 WCi/ml
[Q-32P]ATP for 1 h at room temperature. The gel
was washed several times with 200 ml of 5% TCA,
1% sodium pyrophosphate until the cpm were at
background levels, dried and subjected to autora-
diography.
2.7. Electrophoretic gel mobility shift assay
Growth-arrested SMC were treated with and with-
out linoleic acid (50 WM) in the presence and absence
of cAMP (1 mM) for the indicated time periods and
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nuclear extracts were prepared as described earlier
[40]. Protein^DNA complexes were formed by incu-
bating 5 Wg of nuclear protein in a total volume of
20 Wl consisting of 15 mM HEPES, pH 7.9, 3 mM
Tris-Cl, pH 7.9, 60 mM KCl, 1 mM EDTA, 1 mM
PMSF, 1 mM DTT, 4.5 Wg BSA, 2 Wg poly (dI-dC),
15% glycerol, and 100 000 cpm of 32P-labeled oligo-
nucleotide probe for 20 min at 30‡C. Protein^DNA
complexes were resolved on a 4% polyacrylamide gel
using 0.25UTBE bu¡er (1UTBE=50 mM Tris-
borate, pH 8.3 and 1 mM EDTA). Double-stranded
oligonucleotide (AP-1, 5P-CGCTTGATGAGTCAG-
CCGGAA-3P) was labeled with [Q-32P]ATP using a
T4 polynucleotide kinase kit per the supplier’s pro-
tocol (Promega). Unincorporated nucleotides were
removed by chromatography in a G-25 spin column
(Bio-Rad, Richmond, VA).
2.8. cAMP assay
Growth-arrested SMC were treated with and with-
out linoleic acid (50 WM) for 10 min and the intra-
cellular cAMP was measured using cAMP enzyme
immunoassay kit according to the supplier’s proto-
col.
All the experiments were repeated at least three
times with a similar pattern of results.
3. Results and discussion
To understand the signal transduction pathways of
linoleic acid-induced growth in SMC, we studied the
e¡ect of cAMP on linoleic acid-induced DNA syn-
thesis and cell number. Growth-arrested SMC were
treated with and without linoleic acid (50 WM) in the
presence and absence of cAMP (1 mM) for 24 h and
DNA synthesis was determined by [3H]thymidine
uptake into TCA-precipitable counts per minute. Li-
noleic acid induced SMC DNA synthesis 3-fold as
compared to untreated cells (Fig. 1A). cAMP signi¢-
cantly inhibited both basal and linoleic acid-induced
DNA synthesis. To con¢rm these ¢ndings, we next
studied the e¡ect of cAMP on SMC number. Lino-
leic acid caused a 40% increase in SMC number as
determined by MTT assay over a 4 day time period
and this e¡ect was signi¢cantly suppressed by cAMP
(Fig. 1B). Earlier reports showed that cAMP inhibits
growth factor-induced DNA synthesis by blocking
the ‘ERK MAPK’ pathway at the Raf-1 level [18^
20]. To test whether cAMP inhibition of linoleic
acid-induced growth in SMC is due to its interference
with the ‘ERK MAPK’ pathway, we determined the
e¡ect of cAMP on linoleic acid-induced ERKs acti-
vation. Linoleic acid activated ERK2 (p42) as deter-
mined by the slower migration of phosphorylated
ERKs compared to non-phosphorylated forms on
Fig. 1. cAMP inhibits linoleic acid-induced SMC growth.
Growth-arrested SMC were treated with and without linoleic
acid (50 WM) in the presence and absence of cAMP (1 mM) for
24 h for determination of DNA synthesis (A) or 96 h for cell
counts (B). DNA synthesis was determined by [3H]thymidine
uptake and the cell number was measured by MTT assay.
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SDS-PAGE (Fig. 2). In a parallel experiment, equal
amounts of protein (100 Wg) from each condition was
immunoprecipitated with rabbit polyclonal anti-
ERK2 antibodies and the immunocomplexes were
subjected to in-gel kinase assay using myelin basic
protein as a substrate. In-gel kinase assay of immu-
noprecipitated ERK2 showed a 5-fold increase in its
activity in linoleic acid-treated SMC compared to
that in untreated cells. Treatment of SMC with
cAMP alone caused a 5-fold increase in the activa-
tion of ERK2 and exhibited an additive e¡ect with
linoleic acid (Fig. 2).
A large body of evidence indicates that transcrip-
tional factor AP-1 plays an important role in ago-
nist-induced cell growth [41]. AP-1 is formed by di-
merization of fos and jun proteins [42,43]. ERKs
modulate AP-1 activity via induction of expression
of its constituents such as c-fos [7,8]. To understand
the possible mechanism(s) by which cAMP a¡ects
linoleic acid-induced SMC growth, we studied its ef-
fect on the induction of expression of c-fos, c-jun,
jun-B, and jun-D by linoleic acid. Growth-arrested
SMC were treated with and without linoleic acid (50
WM) in the presence and absence of cAMP (1 mM)
for 2 h. Equal amounts of protein (40 Wg) from each
condition were analyzed by Western blotting for
c-fos, c-jun, jun-B and jun-D using their respective
antibodies. Linoleic acid induced the expression of
c-fos, c-jun, and jun-B by 2^3-fold in growth-arrested
SMC (Fig. 3). cAMP alone induced the expression of
c-fos and jun-B and caused an additive e¡ect with
linoleic acid. In contrast, cAMP completely inhibited
linoleic acid-induced c-jun expression. Signi¢cant lev-
els of jun-D were detected in growth-arrested SMC
and these levels were not a¡ected by treatment with
linoleic acid or cAMP, alone or in combination.
Since cAMP mimicked linoleic acid in the activation
of ERK2 and induction of expression of c-fos and
jun-B, it is possible that some of these linoleic acid-
stimulated signaling events are mediated via produc-
tion of cAMP. To test this growth-arrested SMC
were treated with and without linoleic acid (50 WM)
for 10 min and the intracellular cAMP levels were
measured by enzyme immunoassay kit. No signi¢-
cant changes were observed in cAMP levels between
control and linoleic acid-treated SMC (control,
425 þ 64 fmol/well vs. linoleic acid treatment,
350 þ 64 fmol/well).
Fig. 3. cAMP exhibits di¡erential e¡ects on linoleic acid-in-
duced expression of early response protooncogenes. Growth-ar-
rested SMC were treated with and without linoleic acid (50 WM)
in the presence and absence of cAMP (1 mM) for 2 h and cell
lysates were prepared. Forty micrograms of protein from con-
trol and each treatment was analyzed by Western blotting for
c-fos, c-jun, jun-B, and jun-D using their respective antibodies.
Fig. 2. cAMP does not block linoleic acid-induced activation of
ERKs. Upper panel: growth-arrested SMC were treated with
and without linoleic acid (50 WM) in the presence and absence
of cAMP (1 mM) for 10 min and cell lysates were prepared.
Equal amount of protein (40 Wg/lane) from control and each
treatment was analyzed by Western blotting for ERKs activa-
tion. Phosphorylated ERKs migrate slower than the non-phos-
phorylated ERKs. Lower panel: 200 Wg of protein from control
and each treatment was immunoprecipitated with anti-ERK2
antibodies and the immunoprecipitates were subjected to in-gel
kinase assay using MBP as a substrate.
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Because c-jun can form functional AP-1 either by
its homodimerization or heterdimerization with
c-fos, and linoleic acid-induced c-jun expression is
decreased by cAMP, it is logical to suspect that
cAMP inhibition of linoleic acid-induced growth
Fig. 4. Linoleic acid and cAMP induce AP-1 activity. Five mi-
crograms of nuclear protein from control cells and cells that
were treated with linoleic acid (50 WM) in the presence and ab-
sence of cAMP (1 mM) for various time periods was incubated
with 32P-labeled canonical AP-1 oligonucleotide and the pro-
tein^DNA complex was separated on a 4% non-denaturing
polyacrylamide gel.
C
Fig. 5. cAMP and forskolin antagonize linoleic acid-induced
p27kip1 depletion and CDK2 activation. Growth-arrested SMC
were treated with and without linoleic acid (50 WM) in the pres-
ence and absence of cAMP (1 mM) (A) or forskolin (10 WM)
(B) for the indicated time periods and cell lysates were pre-
pared. Upper panel: 40 Wg of protein from control and each
treatment was analyzed by Western blotting for p27kip1 using
its speci¢c antibodies. Lower panel : cell lysates containing equal
amount of protein (300 Wg) were immunoprecipitated with anti-
CDK2 antibodies and the CDK2 activity in the immunoprecipi-
tates was measured using histone H1 as a substrate. The prod-
ucts were separated on 0.1% SDS^12% polyacrylamide gel,
dried and subjected to autoradiography.
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may be due to its interference with AP-1 activity. To
investigate whether this is the case, nuclear extracts
were prepared from SMC treated with and without
linoleic acid (50 WM) in the presence and absence of
cAMP (1 mM) for various time periods, and ana-
lyzed for AP-1 activity by electrophoretic gel mobil-
ity shift assay (EMSA) using 32P-labeled AP-1 can-
onical oligonucleotide. As expected, linoleic acid
induced AP-1 activity 4-fold (Fig. 4). Increases in
AP-1 activity in response to linoleic acid were ob-
served at 1 h, reached maximum 4-fold by 2 h, and
these levels persisted for at least 4 h. cAMP alone
increased AP-1 activity and caused an additive e¡ect
with linoleic acid. These results suggest that cAMP
inhibits linoleic acid-induced SMC growth without
interference with the AP-1 activity.
cAMP was reported to block colony-stimulating
factor-induced growth in macrophages by increasing
the level of p27kip1, a CDKI, and thereby inhibiting
CDK4 activity [36]. p27kip1 has been reported to in-
hibit CDK2 activity as well [35]. Cyclin E-CDK2
plays an important role in the progression of cells
from G1 to S phase [31^33]. To investigate whether
linoleic acid activates cyclin E-CDK2 activity and if
so, whether cAMP a¡ects this enzymatic activity
leading to growth inhibition, we studied the e¡ect
of linoleic acid on the steady-state levels of p27kip1
and CDK2 activity in the presence and absence of
cAMP. Linoleic acid treatment of SMC resulted in a
time-dependent decrease (2-fold) in the steady-state
levels of p27kip1 and a time-dependent increase (4-
fold) in CDK2 activity (Fig. 5A). These e¡ects
were antagonized by cAMP. To determine whether
agents that increase intracellular cAMP levels also
prevent linoleic acid-induced depletion of p27kip1,
we studied the e¡ect of forskolin. Forskolin signi¢-
cantly reduced the ability of linoleic acid to deplete
p27kip1 levels in a time-dependent manner (Fig. 5B).
Forskolin also inhibited linoleic acid-induced CDK2
activity (Fig. 5B). These results suggest that cAMP
inhibition of linoleic acid-induced growth may be
due to its antagonism with p27kip1 depletion and
CDK2 activation induced by linoleic acid.
The present ¢ndings show that cAMP inhibits li-
noleic acid-induced growth in SMC. Several studies
have reported that cAMP inhibits growth factor-in-
duced mitogenesis by antagonizing the ‘ERK
MAPK’ pathway at the Raf-1 level [18^20]. cAMP
inhibition of linoleic acid-induced DNA synthesis ap-
pears to be independent of its e¡ect on the ‘ERK
MAPK’ pathway as it did not a¡ect linoleic acid-
induced ERKs activation. A role for the ‘ERK
MAPK’ pathway in agonist-induced c-fos expression
via phosphorylating and activating Elk1 has been
suggested [16,17]. The ¢nding that cAMP by itself
causes ERKs activation and induces c-fos expression
in SMC agrees with the above notion. Many studies
have demonstrated that jun-B inhibits the transacti-
vating and transforming activities of c-jun by form-
ing inactive heterodimers [44^46]. Although cAMP
induced the expression of jun-B and exhibited an
additive e¡ect with linoleic acid, it is unlikely that
jun-B forms inactive heterodimers with c-jun leading
to decreased AP-1 activity and growth in cAMP-
treated SMC because the expression of c-jun is
down-regulated by this agent. In fact, cAMP in-
creased AP-1 activity and caused an additive e¡ect
with linoleic acid. It is likely that c-fos and jun-B
account for increased AP-1 activity by cAMP as it
induced the expression of these protooncogenes,
which can form a functional AP-1.
A large body of evidence indicates that cyclin-
CDKs play an important role in cell cycle progres-
sion [21^25]. In addition, it was reported that cyclin
E-CDK2 activity plays a rate-limiting role in G1/S
transition [31^33]. Recently it was also reported that
cAMP blocks colony-stimulating factor-induced mi-
togenesis in macrophages by inhibiting cyclin D1-
CDK4 activity via increasing the expression of
p27kip1 [36]. Our results show that linoleic acid is
capable of activating G1/S transition events, such
as p27kip1 depletion and CDK2 activation and these
events are antagonized by cAMP. Linoleic acid-in-
duced increase in CDK2 activity may be mediated
by increased expression of CDK2 or cyclin E or de-
pletion of its inhibitors, such as p27kip1. cAMP in-
hibition of linoleic acid-induced CDK2 activity may
be explained by several mechanisms: cAMP may in-
duce the expression of p27kip1 or inhibit a signal
transduction pathway leading to its depletion. The
¢rst possibility appears unlikely because cAMP alone
has no e¡ect on the steady-state levels of p27kip1. It is
also possible that cAMP inhibits the degradation of
other CDKIs such as p21cip1=waf1 or the INK4 family
members. Alternatively, cAMP can inhibit the ex-
pression of cyclin E and therefore reduce CDK2 ac-
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tivity. Future studies should address which of these
mechanisms are operative in cAMP inhibition of
CDK2 activity. The present ¢ndings together with
those of Kato et al. [36] and others [18^20] clearly
suggest that cAMP can a¡ect agonist-induced
growth by interfering with various signal transduc-
tion pathways, including the cyclin-CDK and ‘ERK
MAPK’ pathways that play an essential role in cell
cycle progression.
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